Bordetella pertussis Isolates with a Heterogeneous Phenotype for Erythromycin Resistance

Authors:

Abstract
Erythromycin is currently being used for both prophylaxis and treatment of pertussis infections. Erythromycin resistance was first recognized in Bordetella pertussis in Arizona in 1994, and since then, three additional resistant isolates have been identified in the United States. To better assess the potential public health impact of erythromycin-resistant B. pertussis , we used the disk diffusion assay to evaluate the frequency of erythromycin resistance among 1,030 recently circulating U.S. isolates and found the rate of occurrence to be B. pertussis isolates and their potential association with changing pertussis epidemiology.

This publication has 7 references indexed in Scilit: